Demand forweight-loss drugs has grown at an astonishing rate in recent years, driving share prices of healthcare giants such ...

The new weight-loss drugs were originally developed as a treatment for type ... While a tablet form of semaglutide is already available, this was initially approved as a low-dose version that is less ...

Some oncologists are turning to GLP-1 agents to help patients shed excess pounds, with the goal of improving cancer outcomes.

U.S. representative from Austin asks Health and Human Services secretary to push for generic licensing of semaglutide ...

Some people have turned to compound pharmacies to replace drugs in short supply, but medical professionals warn of a new ...

Ongoing shortages of popular weight loss and diabetes drugs in the U.S. have spurred fierce competition between established drugmakers and an emerging market of compounded versions as telehealth ...

The future of oral weight loss medication looks bright. Drug manufacturer Novo Nordisk announced a new experimental ...

The shortage of popular diabetes and weight-loss drugs known as GLP-1s — and insurers’ uneven coverage of them — is putting an unprecedented supply of compounded drugs in consumers' medicine cabinets.

The Bristol Myers Squibb medicine is said relieve symptoms without causing some of the harsh side effects of drugs already in use. Meanwhile, thousands of patients allege in a lawsuit that drugs used ...

But Lilly isn't alone in the market, and in the coming years, this space could become more crowded. Today, Lilly competes ...

The injection has previously been used to treat diabetes , but has faced criticism in recent months after a string of celebs ...

The Food and Drug Administration, as expected, approved KarXT, the first new type of drug for schizophrenia in decades. It appears to be effective, but its main advantage is milder side effects.